
Immatics NV
IMTXHealthcare|Biotechnology|Germany
$9.68
-0.28 (-2.81%)
Tangible Book
$3.84
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
45.77,
52.76,
115.49,
260.33,
498.14
],
"ebit_estimate": [
-298.2,
-308.77,
-286.36,
-227.79,
-107.98
],
"ebitda_estimate": [
-271.08,
-300.28,
-337.6,
-331.01,
-189.08
],
"net_income_estimate": [
-270.19,
-293.42,
-298.71,
-217.17,
-94.35
],
"per_share_eps_estimate": [
-1.98,
-1.95,
-1.71,
-1.02,
-0.22
],
"eps_nri_estimate": [
-1.98,
-1.95,
-1.71,
-1.02,
-0.22
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
4.69,
4.2,
2.41,
2.52,
2.35
],
"pretax_income_estimate": [
-270.53,
-293.52,
-298.71,
-217.17,
-94.35
],
"operating_cash_flow_per_share_estimate": [
-1.6,
-1.17,
-1.67,
-1.15,
0.02
],
"roa_estimate": [
-39,
-38.5,
-47.1,
-40.5,
-5.7
],
"roe_estimate": [
-46.88,
-43.3,
-53.5,
-50,
-7.5
],
"gross_margin_estimate": [
100,
75,
75.5,
76,
78.55
],
"operating_cash_flow_estimate": [
-215.24,
-156.81,
-224.45,
-154.31,
3.12
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "26.64",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 26.64,
"future_ebit_estimate_growth": -10.48,
"future_ebitda_estimate_growth": -19.36,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -9.88,
"future_pretax_income_estimate_growth": -9.54,
"future_book_value_per_share_estimate_growth": -16.17,
"future_roa_estimate_growth": -12.98,
"future_roe_estimate_growth": -8.78,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
11.99,
11.39,
13.54,
4.57,
4.57,
4.57,
21.69
],
"ebit_estimate": [
-72.55,
-75.17,
-73.61,
-79.36,
-81.35,
-83.35,
-72.79
],
"ebitda_estimate": [
-73.21,
-74.05,
-66.26,
null,
null,
null,
null
],
"net_income_estimate": [
-65.77,
-68.95,
-65.57,
-75.07,
-77.19,
-79.36,
-68.97
],
"per_share_eps_estimate": [
-0.49,
-0.51,
-0.48,
-0.57,
-0.59,
-0.59,
-0.52
],
"eps_nri_estimate": [
-0.49,
-0.51,
-0.48,
-0.57,
-0.59,
-0.59,
-0.52
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-65.51,
-69.19,
-67.11,
-75.07,
-77.19,
-79.36,
-68.97
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
100,
100,
100,
75
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "26.64",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 26.64,
"future_ebit_estimate_growth": -10.48,
"future_ebitda_estimate_growth": -19.36,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -9.88,
"future_pretax_income_estimate_growth": -9.54,
"future_book_value_per_share_estimate_growth": -16.17,
"future_roa_estimate_growth": -12.98,
"future_roe_estimate_growth": -8.78,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}